Efficacy and Safety of Risperidone in the Treatment of Schizoaffective Disorder

“…In addition, paliperidone extended-release, risperidone (Janicak et al ., 2001), ziprasidone (Keck et al ., 2001) and aripiprazole (Glick et al ., 2009) have all proven their effectiveness and safety in randomized clinical trials. Lithium (Greil et al ., 1997; Maj, 1988) and risperidone (Izáková et al ., 2009) have also shown effectiveness in open clinical trials, and finally, there are some observational studies for lithium and carbamazepine (Baethge et al ., 2004), clozapine (Ciapparelli et al ., 2003), risperidone (Vieta et al ., 2001) and long-acting risperidone injection (Lasser et al ., 2004).…”

Section: Introductionmentioning

confidence: 99%

A retrospective naturalistic study on the psychopharmacological treatment of schizoaffective disorder

Muñoz-Negro

Bailón²,

Rivera³

et al. 2021

International Clinical Psychopharmacology

View full text Add to dashboard Cite

Evidence on the effectiveness of psychopharmacological treatment of schizoaffective disorder is scarce and mostly comes from indirect, nonspecific sources. We carried out a large retrospective study (n = 770) of every other consecutively numbered clinical record with a recorded ICD-10 diagnosis of schizoaffective disorder in the Andalusian Health Service record system. We gathered sociodemographic, drug treatment and clinical outcomes such as improvement, relapses and change over time on DSM-5 psychotic dimensions. We analyzed data to explore associations between drug use and clinical improvement. Antipsychotics were the most commonly used drugs (77%). 22.4% of patients experienced at least a mild improvement. Clozapine (odds ratio [OR] = 2.4) and aripiprazole (OR = 2.3) for global improvement, and quetiapine (OR = 3.5) for depression were the most effective drugs. Antidepressants, mood stabilizers and benzodiazepines were also associated with a better outcome in some DSM-5 dimensions such as delusions, hallucinations and language, respectively. Antipsychotic monotherapy was not associated with a better outcome. Our findings corroborate the role of antipsychotics as the essential psychopharmacological treatment for different symptoms of schizoaffective disorder. However, the role of mood stabilizers, antidepressants or BZD is controversial and should be individually considered. Int

show abstract

“…In combination with moodstabilizers, risperidone is a safe and effective therapy for the treatment of patients with manic, hypomanic and depressive symptoms of mixed episodes in the bipolar type of schizo-affective disorder (Vieta et al, 2001). It has been shown that atypical antipsychotics significantly reduce smoking and alcohol consumption in schizophrenic patients.…”

Section: Introductionmentioning

confidence: 99%

Low dose risperidone attenuates cue-induced but not heroin-induced reinstatement of heroin seeking in an animal model of relapse

Lai

Chen

Zhu

et al. 2013

International Journal of Neuropsychopharmacology

View full text Add to dashboard Cite

The aim of the present study was to investigate the effects of pretreatment with risperidone on heroin self-administration and heroin-seeking behaviour induced by cues and heroin priming. Rats were trained to self-administer heroin under a fixed ratio 1 schedule for 2 wk and nose-poke responding was extinguished for 10 d, after which reinstatement of drug seeking was induced by conditioned cues or heroin priming. Acute risperidone administration at doses 10-100 μg/kg potently and dose-dependently inhibited reinstatement of conditioned cue-induced heroin seeking; the minimum dose of inhibition was 30 μg/kg. In contrast, risperidone at the same doses did not attenuate reinstatement induced by two priming doses of heroin (100 or 250 μg/kg s.c.). Risperidone at these doses failed to alter heroin self-administration and locomotion activity. These data demonstrate that acute treatment with low-dose risperidone inhibits conditioned cue-induced heroin seeking and risperidone may be an adjunctive therapy for the treatment of heroin addiction.

show abstract

Efficacy and Safety of Risperidone in the Treatment of Schizoaffective Disorder

Cited by 31 publications

References 0 publications

Long-Acting Risperidone in Young Adults with Early Schizophrenia or Schizoaffective Illness

Long-Acting Risperidone in Young Adults with Early Schizophrenia or Schizoaffective Illness

A retrospective naturalistic study on the psychopharmacological treatment of schizoaffective disorder

Low dose risperidone attenuates cue-induced but not heroin-induced reinstatement of heroin seeking in an animal model of relapse

Contact Info

Product

Resources

About